Catalyst calendar
When the active studies of the companies we follow are expected to reach primary completion, the point where the main results can be analysed.
How to read this. The date is the sponsor's own estimate in ClinicalTrials.gov. Topline results usually follow some weeks or months later, and dates often move. More about primary completion. Data fetched 7 October 2026.
2026
| Primary completion | Company | Phase | Status | Condition and study |
|---|---|---|---|---|
| Dec 2026 | Beam Therapeutics | N/A | Recruiting | Sickle Cell Trait Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT) · NCT06071377 |
| Dec 2026 | Beam Therapeutics | Phase 1/2? | Active, not recruiting | Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) · NCT05885464 |
2027
| Primary completion | Company | Phase | Status | Condition and study |
|---|---|---|---|---|
| 19 May 2027 | Circio Holding ASA | Phase 1/2? | Recruiting | Multiple Myeloma, Smoldering Multiple Myeloma The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma · NCT05841550 |
| 6 Jun 2027 | CRISPR Therapeutics | Phase 3? | Active, not recruiting | Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) · NCT05329649 |
| 9 Jun 2027 | Vertex Pharmaceuticals | Phase 3? | Recruiting | Beta-Thalassemia, Thalassemia, Hematologic Diseases Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease · NCT05477563 |
| Jun 2027 | CRISPR Therapeutics | Phase 1? | Recruiting | Cardiovascular, Metabolic Disease, Dyslipidemias A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias · NCT07491172 |
| Jun 2027 | Circio Holding ASA | Phase 2? | Active, not recruiting | Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer · NCT06015724 |
| Jul 2027 | Intellia Therapeutics | Phase 3? | Recruiting | Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease A Phase 3 Study of NTLA-2001 in ATTRv-PN · NCT06672237 |
| 22 Jul 2027 | Vertex Pharmaceuticals | Phase 2? | Active, not recruiting | Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) · NCT07161037 |
| 30 Sep 2027 | Vertex Pharmaceuticals | Phase 3? | Active, not recruiting | Cystic Fibrosis Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older · NCT06460506 |
| 1 Oct 2027 | Vertex Pharmaceuticals | Phase 4? | Not yet recruiting | Ankle Osteoarthritis, Postoperative Pain, Acute Pain Suzetrigine for Postoperative Pain After Total Ankle Replacement · NCT07795827 |
| 14 Nov 2027 | CRISPR Therapeutics | Phase 3? | Active, not recruiting | Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) · NCT05356195 |
| Dec 2027 | Intellia Therapeutics | Phase 3? | Recruiting | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) · NCT06128629 |
| 28 Dec 2027 | Vertex Pharmaceuticals | Phase 4? | Enrolling by invitation | Pain, Acute Postoperative, Breast Disease Suzetrigine for Non-Mastectomy Breast Surgery · NCT07463430 |
| 30 Dec 2027 | Beam Therapeutics | Phase 1/2? | Recruiting | Glycogen Storage Disease Type Ia A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) · NCT06735755 |
| 31 Dec 2027 | Vertex Pharmaceuticals | Phase 3? | Recruiting | Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes · NCT04786262 |
2028
| Primary completion | Company | Phase | Status | Condition and study |
|---|---|---|---|---|
| Jan 2028 | Vertex Pharmaceuticals | Phase 4? | Not yet recruiting | Postoperative Pain Suzetrigine Added to Multimodal Analgesia for Women Undergoing Minimally Invasive Hysterectomy · NCT07836010 |
| Feb 2028 | Beam Therapeutics | Phase 1/2? | Active, not recruiting | Sickle Cell Disease BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease · NCT05456880 |
| May 2028 | Beam Therapeutics | Phase 1/2? | Recruiting | Alpha 1-Antitrypsin Deficiency A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) · NCT06389877 |
| 2 Jun 2028 | Vertex Pharmaceuticals | Phase 2/3? | Recruiting | Proteinuric Kidney Disease Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease · NCT05312879 |
| 1 Jul 2028 | CRISPR Therapeutics | Phase 1/2? | Recruiting | Hypertension A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension · NCT07758634 |
| Aug 2028 | Vertex Pharmaceuticals | Phase 4? | Not yet recruiting | Knee Arthritis, Knee Osteoarthritis Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty · NCT07624526 |
| 29 Dec 2028 | Vertex Pharmaceuticals | Phase 2/3? | Recruiting | Primary Membranous Nephropathy Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) · NCT07204275 |
2029
| Primary completion | Company | Phase | Status | Condition and study |
|---|---|---|---|---|
| 30 Jan 2029 | Vertex Pharmaceuticals | Phase 2? | Enrolling by invitation | Myotonic Dystrophy Type 1 (DM1) A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I · NCT06926621 |
| 2 Feb 2029 | Cereno Scientific AB | Phase 2? | Not yet recruiting | Pulmonary Arterial Hypertension CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension · NCT07761572 |
| 2 Mar 2029 | Vertex Pharmaceuticals | Phase 2? | Recruiting | Myasthenia Gravis, Generalized A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis · NCT07501702 |
| 30 May 2029 | Beam Therapeutics | Phase 1? | Recruiting | T-Cell Acute Lymphoblastic Leukemia/Lymphoma Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma · NCT06934382 |
| 30 Jul 2029 | Vertex Pharmaceuticals | Phase 3? | Enrolling by invitation | Cystic Fibrosis Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older · NCT05844449 |
| 28 Dec 2029 | Vertex Pharmaceuticals | Phase 3? | Enrolling by invitation | Immunoglobulin A Nephropathy A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy · NCT07807995 |
| 30 Dec 2029 | CRISPR Therapeutics | Phase 1/2? | Not yet recruiting | Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease · NCT07804004 |
2030
| Primary completion | Company | Phase | Status | Condition and study |
|---|---|---|---|---|
| Jan 2030 | CRISPR Therapeutics | Phase 1/2? | Recruiting | B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies · NCT05643742 |
| 30 Jun 2030 | Vertex Pharmaceuticals | Phase 3? | Active, not recruiting | Cystic Fibrosis Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age · NCT05422222 |
| 30 Jun 2030 | CRISPR Therapeutics | Phase 1/2? | Not yet recruiting | Alpha-1 Antitrypsin Deficiency (AATD) A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD) · NCT07850076 |
2031
| Primary completion | Company | Phase | Status | Condition and study |
|---|---|---|---|---|
| 31 Dec 2031 | CRISPR Therapeutics | Phase 1? | Recruiting | SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease · NCT06925542 |
2032
| Primary completion | Company | Phase | Status | Condition and study |
|---|---|---|---|---|
| Dec 2032 | Vertex Pharmaceuticals | N/A | Recruiting | DM1, Myotonic Dystrophy, Myotonic Dystrophy 1 Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension · NCT07700225 |
2033
| Primary completion | Company | Phase | Status | Condition and study |
|---|---|---|---|---|
| Dec 2033 | CRISPR Therapeutics | Phase 1/2? | Recruiting | Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease · NCT07549698 |
2034
| Primary completion | Company | Phase | Status | Condition and study |
|---|---|---|---|---|
| 14 Aug 2034 | Intellia Therapeutics | Phase 1/2? | Recruiting | Hemophilia B A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B · NCT06379789 |
2038
| Primary completion | Company | Phase | Status | Condition and study |
|---|---|---|---|---|
| Mar 2038 | Intellia Therapeutics | N/A | Enrolling by invitation | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001 · NCT05697861 |
| Aug 2038 | CRISPR Therapeutics | N/A | Enrolling by invitation | Hematologic Malignancy, Solid Malignancy A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies · NCT06208878 |
2039
| Primary completion | Company | Phase | Status | Condition and study |
|---|---|---|---|---|
| 30 Sep 2039 | CRISPR Therapeutics | Phase 3? | Enrolling by invitation | Beta-Thalassemia, Thalassemia, Sickle Cell Disease A Long-term Follow-up Study in Participants Who Received CTX001 · NCT04208529 |
2040
| Primary completion | Company | Phase | Status | Condition and study |
|---|---|---|---|---|
| Apr 2040 | Intellia Therapeutics | N/A | Enrolling by invitation | Hereditary Angioedema Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002 · NCT06262399 |
2043
| Primary completion | Company | Phase | Status | Condition and study |
|---|---|---|---|---|
| 12 Feb 2043 | Beam Therapeutics | N/A | Recruiting | Hemoglobinopathy, Sickle Cell Disease A Long-term Follow-up Study in Patients Who Received BEAM-101 · NCT07373639 |
Date passed, study still active
The estimated date has passed but the study is still listed as active. Results may be pending, or the sponsor has not updated the record yet.
| Primary completion | Company | Phase | Status | Condition and study |
|---|---|---|---|---|
| 4 Apr 2024 passed |
Intellia Therapeutics | Phase 1/2? | Active, not recruiting | Hereditary Angioedema NTLA-2002 in Adults With Hereditary Angioedema (HAE) · NCT05120830 |
| Dec 2024 passed |
Circio Holding ASA | Phase 2? | Active, not recruiting | Pancreas Cancer Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer · NCT05638698 |
| 29 Jan 2026 passed |
Beam Therapeutics | Phase 1? | Recruiting | Healthy Subjects, Healthy Participant Study This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects · NCT07304791 |
| 10 Feb 2026 passed |
Intellia Therapeutics | Phase 3? | Active, not recruiting | Hereditary Angioedema HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) · NCT06634420 |
| 21 Apr 2026 passed |
Moderna | Phase 1/2? | Active, not recruiting | Cystic Fibrosis A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) · NCT05668741 |